We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Human Genome Sciences, Inc. (MM) | NASDAQ:HGSI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.24 | 0 | 01:00:00 |
From May 2019 to May 2024
GlaxoSmithKline PLC (GSK.LN) plans in the next few weeks to launch an effort to replace the entire board of Human Genome Sciences (HGSI), the target of a $2.6 billion offer by Glaxo which the U.S. company rejected, Reuters reported Wednesday on its website, citing people familiar with the situation.
Glaxo intends to nominate 12 directors to replace Human Genome's board, and has begun a search for candidates. Additionally, Glaxo is expected to extend its tender for Human Genome beyond June 7.
Glaxo declined comment to Reuters. Human Genome was not immediately available for comment, Reuters reported.
Full story at: www.reuters.com/article/2012/05/30/us-humangenome-gsk-idUSBRE84T0XR20120530
-Dow Jones Newswires; 212-416-2900
1 Year Human Genome Sciences Chart |
1 Month Human Genome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
